Acnex filed in Europe

Acnex filed in Europe

The marketing authorization application for Acnex (clindamycin with
tretinoin) has been submitted to the European regulatory authorities.
Acnex is a new product for treatment of mild to severe acne vulgaris.
It's patented and formulated as a once-daily gel. More than 4,000
patients have been included in clinical studies.

“Acnex has the potential to become a leading product in Meda's
portfolio. The product has become a strong brand on the US market. Acnex
is a well documented product that is very effective and well tolerated.
The product will strengthen Meda's European position in dermatology”,
said Anders Lönner, CEO of Meda AB.

The marketing authorization application covers 29 countries using a
decentralised procedure (DCP). Registration in Russia, Turkey and the
CIS countries will follow. More than 30 million patients suffer from
mild to severe acne in the Meda markets.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878